MidWestOne Financial Group Inc. Grows Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN

MidWestOne Financial Group Inc. raised its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 182.0% in the 3rd quarter, Holdings Channel reports. The fund owned 1,097 shares of the biopharmaceutical company’s stock after acquiring an additional 708 shares during the quarter. MidWestOne Financial Group Inc.’s holdings in Regeneron Pharmaceuticals were worth $617,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds also recently added to or reduced their stakes in the stock. Brighton Jones LLC lifted its holdings in shares of Regeneron Pharmaceuticals by 261.8% during the fourth quarter. Brighton Jones LLC now owns 948 shares of the biopharmaceutical company’s stock worth $675,000 after purchasing an additional 686 shares during the period. Dynamic Technology Lab Private Ltd purchased a new position in Regeneron Pharmaceuticals during the 1st quarter worth $226,000. MGO One Seven LLC raised its position in Regeneron Pharmaceuticals by 28.1% during the 2nd quarter. MGO One Seven LLC now owns 483 shares of the biopharmaceutical company’s stock worth $254,000 after buying an additional 106 shares during the last quarter. Sequoia Financial Advisors LLC lifted its stake in shares of Regeneron Pharmaceuticals by 9.0% in the 2nd quarter. Sequoia Financial Advisors LLC now owns 1,761 shares of the biopharmaceutical company’s stock worth $925,000 after acquiring an additional 146 shares during the period. Finally, Envestnet Portfolio Solutions Inc. boosted its holdings in shares of Regeneron Pharmaceuticals by 22.5% in the second quarter. Envestnet Portfolio Solutions Inc. now owns 2,169 shares of the biopharmaceutical company’s stock valued at $1,139,000 after acquiring an additional 398 shares in the last quarter. 83.31% of the stock is owned by institutional investors and hedge funds.

Regeneron Pharmaceuticals Stock Performance

REGN opened at $803.17 on Friday. Regeneron Pharmaceuticals, Inc. has a 1-year low of $476.49 and a 1-year high of $821.11. The stock has a market cap of $84.41 billion, a P/E ratio of 19.33, a P/E/G ratio of 2.16 and a beta of 0.40. The stock’s 50 day simple moving average is $762.17 and its 200 day simple moving average is $665.80. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.13 and a quick ratio of 3.39.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its earnings results on Friday, January 30th. The biopharmaceutical company reported $11.44 EPS for the quarter, topping analysts’ consensus estimates of $10.74 by $0.70. The company had revenue of $3.88 billion for the quarter, compared to the consensus estimate of $3.76 billion. Regeneron Pharmaceuticals had a return on equity of 13.04% and a net margin of 31.41%.Regeneron Pharmaceuticals’s quarterly revenue was up 2.5% compared to the same quarter last year. During the same period in the previous year, the business earned $12.07 earnings per share. As a group, equities analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, March 5th. Investors of record on Friday, February 20th will be paid a $0.94 dividend. This represents a $3.76 dividend on an annualized basis and a yield of 0.5%. The ex-dividend date of this dividend is Friday, February 20th. This is a positive change from Regeneron Pharmaceuticals’s previous quarterly dividend of $0.88. Regeneron Pharmaceuticals’s dividend payout ratio is currently 8.47%.

Wall Street Analysts Forecast Growth

Several research analysts recently issued reports on the stock. UBS Group increased their price target on shares of Regeneron Pharmaceuticals from $595.00 to $660.00 and gave the stock a “neutral” rating in a report on Friday, November 7th. Wall Street Zen upgraded Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Sunday, February 8th. Canaccord Genuity Group raised their price target on Regeneron Pharmaceuticals from $850.00 to $1,057.00 and gave the company a “buy” rating in a report on Thursday, December 4th. Morgan Stanley lifted their price target on Regeneron Pharmaceuticals from $768.00 to $769.00 and gave the company an “equal weight” rating in a research note on Monday, February 2nd. Finally, Cantor Fitzgerald increased their price objective on Regeneron Pharmaceuticals from $740.00 to $800.00 and gave the stock an “overweight” rating in a research report on Monday, February 2nd. Two analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and nine have issued a Hold rating to the company. Based on data from MarketBeat, Regeneron Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus price target of $793.81.

Insider Buying and Selling at Regeneron Pharmaceuticals

In other news, Director Arthur F. Ryan sold 100 shares of the stock in a transaction that occurred on Monday, February 9th. The shares were sold at an average price of $778.53, for a total value of $77,853.00. Following the sale, the director directly owned 17,803 shares in the company, valued at $13,860,169.59. This represents a 0.56% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Bonnie L. Bassler sold 1,500 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Wednesday, January 7th. The stock was sold at an average price of $800.00, for a total value of $1,200,000.00. Following the transaction, the director owned 1,703 shares of the company’s stock, valued at $1,362,400. This represents a 46.83% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last three months, insiders sold 3,636 shares of company stock worth $2,862,920. 7.02% of the stock is owned by corporate insiders.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.